EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amniotic fluid reduces liver fibrosis by attenuating hepatic stellate cell activation

Charles M Bowen, Frederick Ditmars, Naiyou Liu, Jose Marri Abril, David Ajasin, William K Russell, Heather L Stevenson, Eliseo A Eugenin, Jeffrey H Fair, W Samuel Fagg iD

Stem Cells Translational Medicine · 25.06.2025 · 14 (7)

DOI: 10.1093/stcltm/szaf026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 07.07.2025. Verfasst von Charles M Bowen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplant, Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, United States. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Amniotic Fluid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NCATS CTSA KL2, Institute for Translational Sciences, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regardless of the source of injury or metabolic dysfunction, fibrosis is a frequent driver of liver pathology. Excessive liver fibrosis is caused by persistent activation of hepatic stellate cells (HSCs), which is defined by myofibroblast activation (MFA) and the epithelial-mesenchymal transition (EMT). Strategies to prevent or reverse this HSC phenotype will be critical for successful treatment of liver fibrosis. We have previously shown that full-term, cell-free human amniotic fluid (cfAF) inhibits MFA and EMT in fibroblasts in vitro. We hypothesize that cfAF treatment can attenuate HSC activation and limit liver fibrosis. We tested if cfAF could prevent liver fibrosis or HSC activation in murine models of liver damage, 3-dimensional hepatic spheroids, and HSC cultures. Administering cfAF prevented weight loss and the extent of fibrosis in mice with chronic liver damage without stimulating deleterious immune responses. Gene expression profiling and immunostaining indicated that cfAF administration in carbon tetrachloride-treated mice reduced EMT- and MFA-related biomarker abundance and modulated transcript levels associated with liver metabolism, immune regulatory pathways, and cell signaling. cfAF treatment lowered MFA biomarker levels in a dose-dependent manner in ex vivo hepatic spheroids. Treating HSCs with cfAF in vitro strongly repressed EMT. Multiomics analyses revealed that it also attenuates TGFβ-induced MFA and inflammation-associated processes. Thus, cfAF treatment prevents liver fibrosis by safeguarding against persistent HSC activation. These findings suggest that cfAF may be a safe and effective therapy for reducing liver fibrosis and preventing the development of cirrhosis and/or hepatocellular carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsLiver CirrhosisAmniotic FluidAnimalsHumansMiceEpithelial-Mesenchymal TransitionMice, Inbred C57BLMaleFemale

Stichwörter der Autor:innen

amniotic fluidepithelial-mesenchymal transitionhepatic stellate cellliver fibrosismyofibroblast activationregenerative medicine

Autor:innen und Institutionen

  • Division of Transplant, Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • Department of Neurobiology, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • Deparment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • Merakris Therapeutics, RTP Frontier, Research Triangle Park, NC 27709, United States.

ORCID-Profile: W Samuel Fagg

Förderung

  • NIH NCATS CTSA KL2
  • Institute for Translational Sciences
  • NCATS NIH HHS
  • Clinical and Translational Science Award NRSA (TL1) Training Core
  • John L. Hern Chair of Transplant Endowment
  • Mimmie and Halley Smith Endowment
  • CPRIT RP190682

Zitieren

APA

Bowen, C. M., Ditmars, F., Liu, N., Abril, J. M., Ajasin, D., Russell, W. K., Stevenson, H. L., Eugenin, E. A., Fair, J. H., & Fagg, W. S. (2025). Amniotic fluid reduces liver fibrosis by attenuating hepatic stellate cell activation. Stem Cells Translational Medicine, 14(7). https://doi.org/10.1093/stcltm/szaf026

Vancouver

Bowen CM, Ditmars F, Liu N, Abril JM, Ajasin D, Russell WK, et al. Amniotic fluid reduces liver fibrosis by attenuating hepatic stellate cell activation. Stem Cells Translational Medicine. 2025;14(7). doi:10.1093/stcltm/szaf026

BibTeX
@article{Bowen2025,
  author = {Bowen, Charles M and Ditmars, Frederick and Liu, Naiyou and Abril, Jose Marri and Ajasin, David and Russell, William K and Stevenson, Heather L and Eugenin, Eliseo A and Fair, Jeffrey H and Fagg, W Samuel},
  title = {Amniotic fluid reduces liver fibrosis by attenuating hepatic stellate cell activation},
  journal = {Stem Cells Translational Medicine},
  year = {2025},
  volume = {14},
  number = {7},
  doi = {10.1093/stcltm/szaf026}
}
Kostenlos starten →